KCT0007410Recruiting未知
A Phase II study of Oregovomab and PLD in PARP inhibitor Resistant Ovarian, Fallopian tube, or Primary peritoneal cancer patients Not candidate for Platinum Retreatment.
Yonsei University Health System, Severance Hospital0 sites56 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Enrollment
- 56
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional Study
Eligibility Criteria
- Ages
- 20(Year) to o Limit (—)
- Sex
- All
Inclusion Criteria
- •1. Adults 20 years old or older.
- •2. Subjects with histologically confirmed epithelial adenocarcinoma of ovarian, fallopian tube or peritoneal origin
- •3. Eligible histologic epithelial cell types: high grade serous adenocarcinoma, high grade endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, , and low-grade adenocarcinoma, or adenocarcinoma not otherwise specified (N.O.S.). [only up to 5 patients with non-high grade serous carcinoma will be included]
- •4. Prior PARP inhibitor exposure (progressed through a prior PARP inhibitor)
- •5. CA-125 = 50 U/ml
- •6. Prior platinum-based chemotherapy.
- •7. Cohort 1 : 1-3 prior lines of therapies / Cohort 2 : Previous treatments of the 4th line or more
- •8. Not eligible for platinum re-treatment (prior allergic reaction or residual toxicity, patients who are not able to receive (in the physician’s opinion) or willing to receive platinum treatment and platinum resistant patients)
- •9. Received prior bevacizumab or not eligible for bevacizumab due to medical
- •10. Adequate bone marrow function:
- •- a. Absolute neutrophil count (ANC) = 1,500/µL
- •- b. Platelets = 100,000/µL
- •- c. Hemoglobin = 8.0 g/dL (Note: Blood transfusion is permitted up to 48 hours before first dose of study treatment).
- •11. Adequate liver function:
- •- a. Bilirubin < 1.5 times upper limit normal (ULN)
- •- b. Lactate Dehydrogenase (LDH), SGOT/AST and SGPT/ALT < 2.5 times ULN
- •12. Adequate renal function: a. Creatinine = 1.5 times ULN
- •13. ECOG Performance Status of 0 or 1.
- •14. For women of childbearing potential, must be willing to avoid pregnancy by using a highly effective method of contraception from the first dose of study treatment to 60 days after last dose of study treatment.
- •15. Sign informed consent and authorization permitting release of personal health information.
Exclusion Criteria
- •1. Participant has mucinous, germ cell, or borderline tumor of the ovary
- •2. Female subjects who are lactating and breastfeeding, or have a positive serum pregnancy test within 7 days prior to the first dose of study treatment
- •3. Any serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with the completion of treatment according to this protocol.
- •4. Active autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis (MS), or ankylosing spondylitis requiring active disease modifying treatment.
- •5. Known allergy to murine proteins or hypersensitivity to any of the excipients of the oregovomab and PLD.
- •6. Chronically treated with immunosuppressive drugs such as cyclosporine, adrenocorticotropic hormone (ACTH), etc.
- •7. Chronic therapeutic corticosteroid use, defined as > 5 days of prednisone or equivalent, with the exception of inhalers or those on a pre-planned steroid taper.
- •8. Recognized acquired, hereditary, or congenital immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia.
- •9. Clinically significant active infection(s) at the time of screening.
- •10. Any of the following conditions (on-study testing is not required):
- •- a. Known HIV-infected subjects unless on effective anti-retroviral therapy with an undetectable viral load within 6 months, or
- •- b. Known or suspected hepatitis B if active infection (patients with chronic hepatitis B infection must have an undetectable HBV viral load on suppressive therapy, if indicated; positive surface antibody alone is not an exclusion), or
- •- c. Known or suspected hepatitis C infection which has not been treated and cured unless currently on treatment with an undetectable viral load).
- •11. Uncontrolled or life-threatening diseases compromising safety evaluation.
- •12. Participant has a known additional malignancy that is progressing or has required active treatment within the past 2 years
- •Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ, endometrial carcinoma) that have undergone potentially curative therapy are not excluded.
- •Note: Participants with synchronous primary endometrial cancer or a past history of primary endometrial cancer that met the following conditions are not excluded: Stage not greater than IA: no more than superficial myometrial invasion.
- •13. Contraindications to the use of pressor agents
- •14. Undergone more than one surgical debulking or have not recovered from surgery.
- •15. History or evidence upon physical examination of CNS disease, seizures not controlled with standard medical therapy, or any brain metastases.
- •16. Any of the following cardiovascular conditions:
- •- a. Acute myocardial infarction within 6 months before the first dose of study treatment.
- •- b. Current history of New York Heart Association (NYHA) Class III or IV heart failure (see Appendix H).
- •- c. Evidence of current uncontrolled cardiovascular conditions including cardiac arrhythmias, angina, pulmonary hypertension, or electrocardiographic clinically significant findings.
- •17. Unable to read or understand or unable to sign the necessary written consent before starting treatment
- •18. Inability to attend or comply with treatment of follow-up scheduling
Investigators
Similar Trials
Recruiting
Phase 2
Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum RetreatmentPARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum RetreatmentNCT05407584Yonsei University56
Not yet recruiting
Not Applicable
OLAPARIB IN COMBINATION WITH PEMBROLIZUMAB IN HRRM AND/OR HRD POSITIVE CANCER-R11 Nausea and vomitingNausea and vomitingR11PER-029-19Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co. Inc.,7
Active, not recruiting
Phase 1
Olaparib in combination with pembrolizumab in HRRm and HRD positive cancerEUCTR2019-001745-40-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300
Active, not recruiting
Phase 1
Olaparib in combination with pembrolizumab in HRRm and HRD positive cancerEUCTR2019-001745-40-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.300
Active, not recruiting
Phase 1
Olaparib in combination with pembrolizumab in HRRm and HRD positive cancerThe treatment of participants with HRRm and/or HRD-positive cancerMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-503831-17-00Merck Sharp & Dohme LLC425